502-503 / 2351
HPV (p16) oro vs non oro
.
‐
…. our data suggests that patients with p16‐positive tumors of the larynx and
hypopharynx should be considered candidates for enhanced, multimodality
treatment schedules in line with p16‐negative HNSCC.
Lassen et al. RO 2015